Outlook Therapeutics Tanks Over 60% On Another FDA Blow – Here’s How Retail Is Reacting The U.S. health regulatory agency, the FDA, rejected Outlook Therapeutics’ application for approval of its drug Lytenava, which is intended to treat wet AMD.
On Monday, there are stocks with unusual volume. Let's take a look. The trading volume of these stocks is deviating from the norm in today's session.
Thursday's session: top gainers and losers Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.
Let's take a look at the stocks that are in motion in today's session. Curious about what's happening in today's session? Check out the latest stock movements and price changes.
FDA Rejects Outlook Therapeutics Eye Drug For Second Time Outlook Therapeutics shares fall after the FDA rejects its ONS-5010 wet AMD drug application, citing insufficient efficacy evidence despite prior trial success.
The market is filled with gapping stocks in Thursday's session. The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Wondering what's happening in today's pre-market session? Before the opening bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
